ASCO 2020

Questions discussed in this category

HERO study - https://clinicaltrials.gov/ct2/show/NCT03085095

Do you offer enasidenib with azacitadine in AML with an IDH2 mutation for patients ineligible for intensive induction chemotherapy?

Does the absence of an OS benefit in the AG221-AML-005 presented at ASCO 2020 deter you from this strategy?

2 Answers available

Will you offer capecitabine for 1 year to all localized TNBC patients?

Does the SYSUCC-001 trial presented at ASCO 2020 change your practice?

1 Answer available

For muscle invasive bladder cancer, after neoadjuvant chemotherapy with cis/gem and surgery with residual tumor and lymph node involvement, would you consider adjuvant avelumab as an extrapolation base on the JAVELIN 100 results?

https://meetinglibrary.asco.org/record/186872/abstract How do you weigh the negative results from IMvigor 010 of adjuvant atezolizumab vs the results...

2 Answers available

Papers discussed in this category

N. Engl. J. Med.,

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

J. Clin. Oncol., 2019 Dec 05

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).

N. Engl. J. Med., 2020 May 29

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-12-01

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

N Engl J Med, 2020 Sep 19

Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.

J Clin Oncol, 2020 Dec 04

Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics.

N. Engl. J. Med.,

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

ASCO 2020

Questions discussed in this category

Papers discussed in this category

Related Topics